Silent Signals: From Heavy Bleeding to Hidden Sarcoma
By Pharmacist Fang Li-Hua
Case Story
A 44-year-old woman working in finance began experiencing heavy menstrual bleeding with large clots in 2021.
Seeking relief, she paid for high-intensity focused ultrasound (HIFU) at a medical center in June 2023, but the benefit lasted only about six months.
She was later rushed to an emergency department for anemia, where physicians attributed the problem to an endometrial polyp and removed it by hysteroscopy. Ultrasound also revealed adenomyosis.
In early July 2024 her anemia worsened—hemoglobin fell to 5 g/dL (the normal minimum is 10 g/dL)—and she was hospitalized for transfusion. Two weeks later she again had massive vaginal bleeding and visited a gynecology clinic. The doctor suspected adenomyosis as the culprit; after discussion she chose hysterectomy.
In September 2024 she underwent a laparoscopic subtotal hysterectomy. During surgery, adenomyosis and a fibroid were found adherent to the posterior uterine wall; both ovaries, fallopian tubes, and the broad ligaments were normal. After removing the uterine corpus, the surgeon used a morcellator to mince the tissue inside the abdominal cavity so it could be suctioned out through the keyhole incisions. Recovery was uncomplicated.
At her follow-up visit, the pathology report diagnosed low-grade endometrial stromal sarcoma (ESS). Further surgery and treatment were advised.
She sought a second opinion at Koo Foundation Sun Yat-Sen Cancer Center to understand all options.
The Therapeutic Arsenal
The Story of Morcellators
Morcellators—once common in minimally invasive gynecologic surgery—pulverize large tissue masses (such as fibroids) so they can be removed through small laparoscopic ports, giving patients faster recovery and smaller scars.
Problems Identified
In 2014 the U.S. FDA issued a stern warning: if a morcellator shreds tissue that unknowingly contains cancer cells, gas flow within the abdomen can spread those cells, particularly from uterine sarcomas. Although most uterine tumors (fibroids, adenomyosis) are benign, about 1 in 350 women undergoing fibroid surgery may harbor an unsuspected sarcoma, usually discovered only after postoperative pathology. Morcellation can disseminate those malignant cells and worsen outcomes.
Legal and Regulatory Actions
After the FDA warning, manufacturers faced lawsuits alleging that morcellators spread undetected cancer, leading to advanced disease or death. Several major companies halted production.
Current FDA Guidance
The FDA now advises avoiding power morcellators in most fibroid surgeries, especially in women over 50 who have higher occult-cancer risk. If used, containment bags and explicit informed consent are mandatory. Even so, their role in gynecologic surgery remains controversial and tightly controlled.
Disease Explanations
Endometrial Polyp – Localized overgrowth of the uterine lining forming a protruding mass. Usually benign; malignancy risk rises after menopause.
Adenomyosis – Endometrial tissue grows within the uterine muscle, thickening the wall and causing dysmenorrhea, heavy bleeding, and pelvic pain.
Endometrial Stromal Sarcoma (ESS) – Rare uterine cancer from stromal cells of the endometrium.
Low-grade ESS grows slowly.
High-grade ESS grows rapidly and metastasizes readily.
Most cases arise in women aged 40–50 and present with bleeding, pelvic pain, or an abdominal mass. Definitive diagnosis relies on pathology; imaging assesses spread.
Key Takeaways: Early Signs and Prevention of Gynecologic Cancers
Watch for abnormal bleeding – Heavy, prolonged, or clot-filled periods can signal polyps, adenomyosis, or cancers of the cervix and uterine body.
Seek prompt evaluation – Persistent abnormal bleeding warrants ultrasound, blood tests, and other investigations to detect disease early.
Choose appropriate therapy and follow-up – Benign conditions may be observed, medicated, or surgically treated; malignancies require specialist care and a comprehensive pre-treatment work-up.
Value the pathology report – Post-operative pathology reveals future cancer risk, recurrence potential, and the need for additional therapy. Early detection of uterine sarcoma, for instance, guides timely intervention.
This woman’s journey shows that a seemingly simple bleeding problem can hide deeper disease. Early medical attention, thorough evaluation, and tailored treatment markedly cut the risk of progression to gynecologic cancer.